This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FRLN Freeline Therapeutics (FRLN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Freeline Therapeutics Stock (NASDAQ:FRLN) Get Freeline Therapeutics alerts:Sign Up Key Stats Today's Range$6.48▼$6.4850-Day Range$6.43▼$6.4952-Week Range$2.11▼$8.74VolumeN/AAverage Volume12,055 shsMarket Capitalization$28.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. Read More Receive FRLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FRLN Stock News HeadlinesFreeline Therapeutics Shareholders Approve Acquisition by SynconaFebruary 13, 2024 | finanznachrichten.deFreeline Shareholders Approve Acquisition by SynconaFebruary 12, 2024 | finance.yahoo.comWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of AI." Musk's track record includes PayPal, Tesla and SpaceX. Tim Bohen has put the details of what he calls Musk's Mission X into a brand-new masterclass, free to watch with no credit card required. Viewers also receive a free ticker tied to Mission X.November 13 at 1:00 AM | StocksToTrade (Ad)Freeline Therapeutics Holdings plc (FRLN)February 9, 2024 | uk.finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, EAR, PATI, FRLNDecember 1, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX) and Freeline Therapeutics Holdings (FRLN)November 30, 2023 | markets.businessinsider.comFREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline ...November 29, 2023 | businesswire.comFreeline (FRLN) Shares Rise on Merger Agreement With SynconaNovember 23, 2023 | finance.yahoo.comSee More Headlines FRLN Stock Analysis - Frequently Asked Questions How were Freeline Therapeutics' earnings last quarter? Freeline Therapeutics Holdings plc (NASDAQ:FRLN) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($12.90) earnings per share for the quarter, topping analysts' consensus estimates of ($15.20) by $2.30. When did Freeline Therapeutics' stock split? Shares of Freeline Therapeutics reverse split on the morning of Friday, May 12th 2023.The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Freeline Therapeutics IPO? Freeline Therapeutics (FRLN) raised $150 million in an IPO on Friday, August 7th 2020. The company issued 8,823,529 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Freeline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Freeline Therapeutics investors own include SNDL (SNDL), NIO (NIO), Citius Pharmaceuticals (CTXR), Bionano Genomics (BNGO), Cidara Therapeutics (CDTX), Aptose Biosciences (APTO) and Ardelyx (ARDX). Company Calendar Today11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FRLN CIK1810031 Webwww.freeline.life Phone44-0-14-3890-6870FaxN/AEmployees152Year Founded2015Profitability EPS (Trailing Twelve Months)($5.5939) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-150.46% Return on Assets-97.01% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.07 per share Price / Book0.54Miscellaneous Outstanding Shares4,340,000Free Float4,259,000Market Cap$28.12 million OptionableNot Optionable Beta0.66 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:FRLN) was last updated on 4/8/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Freeline Therapeutics Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Freeline Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FRLN Stock Alerts